2024-07-11 17:41:51 ET
Summary
- Regeneron Pharmaceuticals, Inc. stock has increased over 20% in 2024, trading at $1,071 per share at the time of writing.
- Regeneron's valuation is high but arguably justified by potential growth, with impressive revenue and pipeline projections.
- While still a promising investment, a "hold" recommendation is advised due to competition, pipeline setbacks, and operational challenges.
- In this post, I cover the company and its assets in detail and provide product-by-product revenue forecasts, a forward income statement, and a discounted cash flow analysis to support my view.
Investment Overview: Regeneron Recap Illustrates High Valuation, Justified By High Potential
I last covered the Watertown, Massachusetts "Big Pharma" concern Regeneron Pharmaceuticals, Inc. ( REGN ) in a note for Seeking Alpha in January, titled "Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)."...
Read the full article on Seeking Alpha
For further details see:
Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings